United Therapeutics (NASDAQ:UTHR) Given New $463.00 Price Target at Bank of America

Key Points

• Bank of America raised its price target for United Therapeutics from $314.00 to $463.00, indicating a potential upside of 12.69% from the current stock price.
• United Therapeutics shares saw a significant increase, trading up 34.8% during recent trading, reaching $410.85.
• The company reported $6.41 EPS for the last quarter, missing the analysts' consensus estimate of $6.80 by $0.39, despite an 11.7% increase in quarterly revenue compared to the previous year.

United Therapeutics (NASDAQ:UTHR - Get Free Report) had its price objective hoisted by research analysts at Bank of America from $314.00 to $463.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "neutral" rating on the biotechnology company's stock. Bank of America's price target indicates a potential upside of 12.69% from the stock's current price.

Several other research analysts also recently weighed in on UTHR. Morgan Stanley cut their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Wells Fargo & Company dropped their price target on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. HC Wainwright set a $400.00 target price on United Therapeutics and gave the stock a "buy" rating in a report on Thursday, July 31st. Finally, UBS Group raised their price objective on United Therapeutics from $385.00 to $415.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $393.38.

United Therapeutics Trading Up 34.8%

Shares of UTHR stock traded up $106.09 during trading hours on Tuesday, hitting $410.85. The company's stock had a trading volume of 2,157,609 shares, compared to its average volume of 541,179. The company has a 50 day moving average of $299.03 and a 200 day moving average of $304.77. United Therapeutics has a 12-month low of $266.98 and a 12-month high of $436.95. The stock has a market cap of $18.53 billion, a PE ratio of 16.04, a price-to-earnings-growth ratio of 4.62 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.United Therapeutics's quarterly revenue was up 11.7% compared to the same quarter last year. During the same period in the previous year, the company earned $5.85 EPS. As a group, analysts anticipate that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the sale, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total value of $3,079,560.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $10,297,208.76. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,681 shares of company stock valued at $24,537,839 in the last ninety days. 10.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in United Therapeutics during the 1st quarter worth approximately $313,000. Allianz Asset Management GmbH grew its holdings in United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after purchasing an additional 33,254 shares during the period. LPL Financial LLC grew its holdings in United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after purchasing an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC bought a new position in shares of United Therapeutics in the first quarter worth $227,000. Institutional investors own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.